View Document Preview and Link Document Date: 2010-01-20 06:41:38 Open Document File Size: 261,58 KB Share Result on Facebook
City Mu¨nchen / Chicago / / Company Cochrane Schizophrenia Group / MEDLINE / / Country Germany / United States / / Currency USD / / / Facility University of Illinois at Chicago / / IndustryTerm search terms / treatment of positive symptoms / treatment of schizophrenia or related disorders / treatment of overall symptoms / last search / pharmaceutical / / MedicalCondition residual schizophrenia / Alzheimer’s dementia / schizophrenia / NI Chronic / NI Schizophrenia / hebephrenic schizophrenia / schizoaffective disorder / delusional disorder / negative schizophrenia / related disorders / illness / depression / NI Chronic schizophrenia / chronic schizophrenia / schizotypal personality disorder / Mental Disorders / / Organization FDA / University of Illinois at Chicago / Department of Psychiatry and Psychotherapy / / Person OLA NI / AMI AMI AMI AMI / AMI AMI AMI / SER SER SER / ARI ARI ARI ARI / HAL HAL HAL HAL / OLA OLA OLA OLA / / Position www.nature.com/mp / mp / / Product olanzapine / clozapine / Molecular Psychiatry Atypical / haloperidol / Favours Antipsychotic 1.00 Favours Placebo 2.00 Figure 7 Antipsychotic / Sertindole 51 52 53 Ziprasidone 26 55 56 Atypical / I2 / Favours Antipsychotic 1.00 Favours Placebo 2.00 Figure 1 Antipsychotic / Although / Atypical / Olanzapine 431 Molecular Psychiatry 38 Atypical / risperidone / All / / ProvinceOrState Illinois / / URL www.nature.com/mp / / SocialTag 
Molecular Psychiatry[removed], 429–447 & 2009 Nature Publishing Group All rights reserved[removed] $32.00 www.nature.com/mp